Biogen Halts Plans to Develop Tysabri for Stroke After Phase IIb Trial Flop Post author:Sam Post published:February 6, 2018 Post category:BioPharma Natalizumab did not demonstrate improvement in clinical outcomes compared to placebo. Source: BioSpace You Might Also Like Frost & Sullivan Release: Evolving Pharmaceutical Ecosystem Transforms Clinical Trials And Research Outsourcing June 15, 2017 FDA Extends Review for Lipocine's TLANDO; Advisory Committee Meeting Date of January 10, 2018 Rem… November 16, 2017 PTC Therapeutics To Host Conference Call To Discuss Second Quarter Financial Results July 24, 2017
Frost & Sullivan Release: Evolving Pharmaceutical Ecosystem Transforms Clinical Trials And Research Outsourcing June 15, 2017
FDA Extends Review for Lipocine's TLANDO; Advisory Committee Meeting Date of January 10, 2018 Rem… November 16, 2017
